Ravelli Andrea, Roviello Giandomenico, Cretella Daniele, Cavazzoni Andrea, Biondi Alessandra, Cappelletti Maria Rosa, Zanotti Laura, Ferrero Giuseppina, Ungari Marco, Zanconati Fabrizio, Bottini Alberto, Alfieri Roberta, Petronini Pier Giorgio, Generali Daniele
1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
2 Unit of Experimental Oncology, Department of Clinical and Experimental Medicine, Università degli Studi di Parma, Parma, Italy.
Tumour Biol. 2017 Apr;39(4):1010428317695023. doi: 10.1177/1010428317695023.
The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tumor-infiltrating lymphocytes are promising further predictive utility in view of novel immune-related therapeutic strategies which are coming into the clinical setting launching a solid rationale for the future next-generation treatment options. In this scenario, tumor-infiltrating lymphocytes might represent an important resource for the selection of the most appropriate therapeutic strategy, as well as further evaluations of the molecular mechanisms underlying tumor-infiltrating lymphocytes and the immunoediting process would eventually provide new insights to augment therapeutic success. Considering these perspectives, we review the potential utility of tumor-infiltrating lymphocytes in the definition of breast cancer prognosis and in the prediction of treatment outcomes, along with the new promising molecular-based therapeutic discoveries.
近年来，免疫系统作为一种强大的抗肿瘤防御机制的重要性已得到巩固，如今新型免疫相关疗法在多种实体肿瘤的治疗中显示出显著的临床益处。肿瘤浸润淋巴细胞反映了宿主根除恶性肿瘤的努力，在过去几十年中，它们已被证明对乳腺癌具有有趣的预后价值，尤其是在HER2阳性和三阴性分子亚型的情况下。同时，肿瘤浸润淋巴细胞的临床评估已被证明能有效预测新辅助和辅助治疗环境中的治疗结果。目前，鉴于新的免疫相关治疗策略正在进入临床，肿瘤浸润淋巴细胞有望具有进一步的预测价值，这为未来的下一代治疗选择提供了坚实的理论基础。在这种情况下，肿瘤浸润淋巴细胞可能是选择最合适治疗策略的重要资源，对肿瘤浸润淋巴细胞和免疫编辑过程潜在分子机制的进一步评估最终将为提高治疗成功率提供新的见解。考虑到这些观点，我们回顾了肿瘤浸润淋巴细胞在乳腺癌预后定义和治疗结果预测中的潜在用途，以及新的有前景的基于分子的治疗发现。
